Jodi A. McKenzie
About
Jodi A. McKenzie is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Obstetrics and Gynecology.
According to data from OpenAlex, Jodi A. McKenzie has authored 30 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Obstetrics and Gynecology. Recurrent topics in Jodi A. McKenzie's work include Cancer Immunotherapy and Biomarkers (14 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Renal cell carcinoma treatment (8 papers). Jodi A. McKenzie is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Renal cell carcinoma treatment (8 papers). Jodi A. McKenzie collaborates with scholars based in United States, Italy and Spain. Jodi A. McKenzie's co-authors include Douglas Grossman, Tong Liu, H. Atakan Ekiz, Alana L. Welm, Sun-Young Jung, Masatoshi Eto, Robert J. Motzer, Camillo Porta, Viktor Grünwald and Weiyi Peng and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.
In The Last Decade
Jodi A. McKenzie
25 papers receiving 296 citations
Peers
Jodi A. McKenzie
Xiangyan Jiang China
Xiaohong Ma China
Katrin Almstedt Germany
Alba Mota Spain
Rokana Taftaf United States
Perrine Garde‐Granger Canada
Brian C. Willis United States
Sue Ghosh United States
Jinxiao Liang China
Shengwei Mo China
Citations per year, relative to Jodi A. McKenzie Jodi A. McKenzie (= 1×)
peers
Xiangyan Jiang
Countries citing papers authored by Jodi A. McKenzie
Since
Specialization
Citations
This map shows the geographic impact of Jodi A. McKenzie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jodi A. McKenzie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jodi A. McKenzie more than expected).
Fields of papers citing papers by Jodi A. McKenzie
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jodi A. McKenzie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jodi A. McKenzie. The network helps show where Jodi A. McKenzie may publish in the future.
Co-authorship network of co-authors of Jodi A. McKenzie
This figure shows the co-authorship network connecting the top 25 collaborators of Jodi A. McKenzie. A scholar is included among the top collaborators of Jodi A. McKenzie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jodi A. McKenzie. Jodi A. McKenzie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Eskander, Ramez N., Jung‐Yun Lee, Domenica Lorusso, et al.. (2025). TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy. Journal of the National Comprehensive Cancer Network. 23(3.5).
2.
Yonemori, Kan, Keiichi Fujiwara, Kosei Hasegawa, et al.. (2024). Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. Journal of Gynecologic Oncology. 35(2). e40–e40.
3.
Dańska-Bidzińska, Anna, Vanda Salutari, Ali̇ Ayhan, et al.. (2024). 737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study. Annals of Oncology. 35. S561–S561.
4.
Marth, Christian, Richard D. Moore, Mariusz Bidziński, et al.. (2024). Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study. Gynecologic Oncology. 190. S63–S64.
5.
Motzer, Robert J., Toni K. Choueiri, Thomas E. Hutson, et al.. (2024). Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. European Urology. 86(1). 4–9.
6.
Marth, Christian, Richard G. Moore, Mariusz Bidziński, et al.. (2024). #88 Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: primary results of the phase 3 ENGOT-en9/LEAP-001 study. A570.2–A571.
7.
Colomba, Émeline, Domenica Lorusso, Helen Mackay, et al.. (2023). 748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775. Annals of Oncology. 34. S512–S513.
8.
Colombo, Nicoletta, Domenica Lorusso, Bradley J. Monk, et al.. (2023). Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab. The Oncologist. 29(1). 25–35.
9.
Grünwald, Viktor, Thomas Powles, Evgeny Kopyltsov, et al.. (2023). Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. European Urology Oncology. 6(4). 437–446.
10.
Lorusso, Domenica, Nicoletta Colombo, Antonio Casado, et al.. (2023). Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice. European Journal of Cancer. 186. 172–184.
11.
Motzer, Robert J., Camillo Porta, Masatoshi Eto, et al.. (2023). Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology. 41(16_suppl). 4502–4502.
12.
Rha, Sun Young, Toni K. Choueiri, В. Б. Матвеев, et al.. (2023). Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial. International Journal of Cancer. 153(6). 1241–1250.
13.
Lorusso, Domenica, Vicky Makker, Antonio Casado, et al.. (2022). 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775. International Journal of Gynecological Cancer. 32. A102–A102.
14.
Porta, Camillo, Robert J. Motzer, Tomáš Büchler, et al.. (2022). 1449MO Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study. Annals of Oncology. 33. S1205–S1206.
15.
Gaspar, Nathalie, Quentin Campbell‐Hewson, Stefan Bielack, et al.. (2020). 443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082). Annals of Oncology. 31. S1414–S1415.
16.
Gaspar, Nathalie, Quentin Campbell‐Hewson, Stefan Bielack, et al.. (2020). 1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082). Annals of Oncology. 31. S990–S991.
17.
Peng, Weiyi, Leila J. Williams, Chunyu Xu, et al.. (2019). Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma. Clinical Cancer Research. 25(21). 6406–6416.
18.
McKenzie, Jodi A., et al.. (2018). Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica. Pharmacy Practice. 16(4). 1214–1214.
19.
McKenzie, Jodi A., Tong Liu, Sun-Young Jung, et al.. (2013). Survivin promotion of melanoma metastasis requires upregulation of α 5 integrin. Carcinogenesis. 34(9). 2137–2144.
20.
McKenzie, Jodi A., et al.. (2010). Survivin Enhances Motility of Melanoma Cells by Supporting Akt Activation and α5 Integrin Upregulation. Cancer Research. 70(20). 7927–7937.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Xiangyan Jiang Breakdown of academic impact, for papers by Xiaohong Ma Breakdown of academic impact, for papers by Katrin Almstedt Breakdown of academic impact, for papers by Alba Mota Breakdown of academic impact, for papers by Rokana Taftaf Breakdown of academic impact, for papers by Perrine Garde‐Granger Breakdown of academic impact, for papers by Brian C. Willis Breakdown of academic impact, for papers by Sue Ghosh Breakdown of academic impact, for papers by Jinxiao Liang Breakdown of academic impact, for papers by Shengwei Mo